<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39081289</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-0042</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>16</Day></PubDate></JournalIssue><Title>iScience</Title><ISOAbbreviation>iScience</ISOAbbreviation></Journal><ArticleTitle>Case-control study on post-COVID-19 conditions reveals severe acute infection and chronic pulmonary disease as potential risk factors.</ArticleTitle><Pagination><StartPage>110406</StartPage><MedlinePgn>110406</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">110406</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.isci.2024.110406</ELocationID><Abstract><AbstractText>Post-COVID-19 conditions (long COVID) has impacted many individuals, yet risk factors for this condition are poorly understood. This retrospective analysis of 88,943 COVID-19 patients at a multi-state US health system compares phenotypes, laboratory tests, medication orders, and outcomes for 1,086 long-COVID patients and their matched controls. We found that history of chronic pulmonary disease (CPD) (odds ratio: 1.9, 95% CI: [1.5, 2.6]), migraine (OR: 2.2, [1.6, 3.1]), and fibromyalgia (OR: 2.3, [1.3, 3.8]) were more common for long-COVID patients. During the acute infection phase long COVID patients exhibited high triglycerides, low HDL cholesterol, and a high neutrophil-lymphocyte ratio; and were more likely hospitalized (5% vs. 1%). Our findings suggest severity of acute infection and history of CPD, migraine, chronic fatigue syndrome (CFS), or fibromyalgia as risk factors for long COVID. These results suggest that suppressing acute disease severity proactively, especially in patients at high risk, can reduce incidence of long COVID.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Pritha</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>nference Labs, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niesen</LastName><ForeName>Michiel J M</ForeName><Initials>MJM</Initials><AffiliationInfo><Affiliation>nference, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawlowski</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>nference, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandi</LastName><ForeName>Hari</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>nference, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Unice</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>nference, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenehan</LastName><ForeName>Patrick J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>nference, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar-M</LastName><ForeName>Praveen</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>nference Labs, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadig</LastName><ForeName>Mihika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>nference, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>nference, Inc., 18 3rd St. S.W., Rochester, MN 55902, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ardhanari</LastName><ForeName>Sankar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>nference, Inc., 2424 Erwin Road, Durham, NC 27705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Horo</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatakrishnan</LastName><ForeName>A J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>nference, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Clifford J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Maine Medical Center, Portland, ME 04102, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>RECOVER Maine, MaineHealth Institute for Research, Scarborough, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Telenti</LastName><ForeName>Amalio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vir Biotechnology, Inc., San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurt</LastName><ForeName>Ryan T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soundararajan</LastName><ForeName>Venky</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>nference Labs, Bengaluru, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>nference, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>nference, Inc., 18 3rd St. S.W., Rochester, MN 55902, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>nference, Inc., 2424 Erwin Road, Durham, NC 27705, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anumana, Inc., Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>iScience</MedlineTA><NlmUniqueID>101724038</NlmUniqueID><ISSNLinking>2589-0042</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2022 Dec 01:2022.11.30.22282831. doi: 10.1101/2022.11.30.22282831</RefSource><PMID Version="1">36523407</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immunology</Keyword><Keyword MajorTopicYN="N">Public health</Keyword><Keyword MajorTopicYN="N">Respiratory medicine</Keyword></KeywordList><CoiStatement>P.G. was an employee of nference and is a current employee of ConcertAI and has financial interests in these companies and the successful application of this research. M.N., C.P., H.B., U.Y., P.L., P.K., M.N., J.R., S.A., and A.V. are employees of nference and have financial interests in the company and in the successful application of this research. V.S. is an employee of nference and Anumana and has financial interests in these companies and in the successful application of this research. J.O. has received small grants from nference, Inc., and personal consulting fees from Bates College and Elsevier Inc. All of these activities are outside of the present work. R.H. has received a small grant from nference, Inc. and Zealand Pharmaceuticals, and consulting fees from Nestle Nutrition. C.R. acknowledges funding from the National Institutes of Health (1OT2HL162096-01). A.T. is an employee and shareholder of Vir Biotechnology Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>31</Day><Hour>4</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39081289</ArticleId><ArticleId IdType="pmc">PMC11284568</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2024.110406</ArticleId><ArticleId IdType="pii">S2589-0042(24)01631-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clarke K.E.N., Jones J.M., Deng Y., Nycz E., Lee A., Iachan R., Gundlapalli A.V., Hall A.J., MacNeil A. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022. MMWR Morb. Mortal. Wkly. Rep. 2022;71:606&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9098232</ArticleId><ArticleId IdType="pubmed">35482574</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  COVID Data Tracker. Centers for Disease Control and Prevention. 2020. https://covid.cdc.gov/covid-data-tracker</Citation></Reference><Reference><Citation>Tan B.K.J., Han R., Zhao J.J., Tan N.K.W., Quah E.S.H., Tan C.J.-W., Chan Y.H., Teo N.W.Y., Charn T.C., See A., et al. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. BMJ. 2022;378 doi: 10.1136/bmj-2021-069503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069503</ArticleId><ArticleId IdType="pmc">PMC9326326</ArticleId><ArticleId IdType="pubmed">35896188</ArticleId></ArticleIdList></Reference><Reference><Citation>A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Long COVID. 2022. https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm#technical_notes</Citation></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., Myles P., Williams T., Gokhale K.M., Taverner T., Chandan J.S., Brown K., Simms-Williams N., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 2022;28:1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Laughlin K.N., Thompson M., Hota B., Gottlieb M., Plumb I.D., Chang A.M., Wisk L.E., Hall A.J., Wang R.C., Spatz E.S., et al. Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): A longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection. PLoS One. 2022;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893622</ArticleId><ArticleId IdType="pubmed">35239680</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVER  . Researching COVID to Enhance Recovery RECOVER: Researching COVID to Enhance Recovery. 2022. https://recovercovid.org/</Citation></Reference><Reference><Citation>Wagner T., Shweta F.N.U., Murugadoss K., Awasthi S., Venkatakrishnan A.J., Bade S., Puranik A., Kang M., Pickering B.W., O&#x2019;Horo J.C., et al. Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis. Elife. 2020;9 doi: 10.7554/eLife.58227.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.58227</ArticleId><ArticleId IdType="pmc">PMC7410498</ArticleId><ArticleId IdType="pubmed">32633720</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatakrishnan A.J., Pawlowski C., Zemmour D., Hughes T., Anand A., Berner G., Kayal N., Puranik A., Conrad I., Bade S., et al. Mapping each pre-existing condition&#x2019;s association to short-term and long-term COVID-19 complications. NPJ Digit. Med. 2021;4:117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8316410</ArticleId><ArticleId IdType="pubmed">34315980</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurry R., Lenehan P., Awasthi S., Silvert E., Puranik A., Pawlowski C., Venkatakrishnan A.J., Anand P., Agarwal V., O&#x2019;Horo J.C., et al. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med (N Y) 2021;2:965&#x2013;978.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248717</ArticleId><ArticleId IdType="pubmed">34230920</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J.&#xa0;Chronic Dis. 1987;40:373&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Zhang Y., Zhao X., Tao M., Yan W., Fu Y. Hypoalbuminemia&#xa0;&#x2013; An Indicator of the Severity and Prognosis of COVID-19 Patients: A Multicentre Retrospective Analysis. Infect. Drug Resist. 2021;14:3699&#x2013;3710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8437137</ArticleId><ArticleId IdType="pubmed">34526790</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S., Bae J.H., Kwon H.-S., Nauck M.A. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat. Rev. Endocrinol. 2021;17:11&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7664589</ArticleId><ArticleId IdType="pubmed">33188364</ArticleId></ArticleIdList></Reference><Reference><Citation>Montefusco L., Ben Nasr M., D&#x2019;Addio F., Loretelli C., Rossi A., Pastore I., Daniele G., Abdelsalam A., Maestroni A., Dell&#x2019;Acqua M., et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat. Metab. 2021;3:774&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931026</ArticleId><ArticleId IdType="pubmed">34035524</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett C.E., Koyama A.K., Alvarez P., Chow W., Lundeen E.A., Perrine C.G., Pavkov M.E., Rolka D.B., Wiltz J.L., Bull-Otterson L., et al. Risk for Newly Diagnosed Diabetes 30 Days After SARS-CoV-2 Infection Among Persons Aged 18 Years &#x2014; United States, March 1, 2020&#x2013;June 28, 2021. MMWR Morb. Mortal. Wkly. Rep. 2022;71:59&#x2013;65. doi: 10.15585/mmwr.mm7102e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7102e2</ArticleId><ArticleId IdType="pmc">PMC8757617</ArticleId><ArticleId IdType="pubmed">35025851</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherer P.E., Kirwan J.P., Rosen C.J. Post-acute sequelae of COVID-19: A metabolic perspective. Elife. 2022;11 doi: 10.7554/eLife.78200.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.78200</ArticleId><ArticleId IdType="pmc">PMC8942467</ArticleId><ArticleId IdType="pubmed">35318939</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiterer M., Rajan M., G&#xf3;mez-Banoy N., Lau J.D., Gomez-Escobar L.G., Ma L., Gilani A., Alvarez-Mulett S., Sholle E.T., Chandar V., et al. Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2. Cell Metab. 2021;33:2174&#x2013;2188.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8443335</ArticleId><ArticleId IdType="pubmed">34599884</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Col&#xf3;n G.J., Ratnasiri K., Chen H., Jiang S., Zanley E., Rustagi A., Verma R., Chen H., Andrews J.R., Mertz K.D., et al. SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages. Sci. Transl. Med. 2022;14 doi: 10.1126/scitranslmed.abm9151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abm9151</ArticleId><ArticleId IdType="pmc">PMC9529056</ArticleId><ArticleId IdType="pubmed">36137009</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  Public Health Recommendations. Centers for Disease Control and Prevention. 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-public-health-recs.html</Citation></Reference><Reference><Citation>Groenwold R.H.H. Informative missingness in electronic health record systems: the curse of knowing. Diagn. Progn. Res. 2020;4:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371469</ArticleId><ArticleId IdType="pubmed">32699824</ArticleId></ArticleIdList></Reference><Reference><Citation>Tests and procedures. 2020. https://www.mayoclinic.org/tests-procedures</Citation></Reference><Reference><Citation>Test catalog - mayo clinic laboratories. 2022. https://www.mayocliniclabs.com/test-catalog</Citation></Reference><Reference><Citation>Diagnostics  Testing Cleveland Clinic. 2022. https://my.clevelandclinic.org/health/diagnostics</Citation></Reference><Reference><Citation>Medical Tests ucsfhealth.org. 2022. https://www.ucsfhealth.org/medical-tests</Citation></Reference><Reference><Citation>Murugadoss K., Rajasekharan A., Malin B., Agarwal V., Bade S., Anderson J.R., Ross J.L., Faubion W.A., Jr., Halamka J.D., Soundararajan V., Ardhanari S. Building a best-in-class automated de-identification tool for electronic health records through ensemble learning. Patterns (N Y) 2021;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8212138</ArticleId><ArticleId IdType="pubmed">34179842</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  Long COVID or Post-COVID Conditions. Centers for Disease Control and Prevention. 2022. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html</Citation></Reference><Reference><Citation>Pfaff E.R., Girvin A.T., Bennett T.D., Bhatia A., Brooks I.M., Deer R.R., Dekermanjian J.P., Jolley S.E., Kahn M.G., Kostka K., et al. Identifying who has long COVID in the USA: a machine learning approach using N3C data. Lancet. Digit. Health. 2022;4:e532&#x2013;e541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110014</ArticleId><ArticleId IdType="pubmed">35589549</ArticleId></ArticleIdList></Reference><Reference><Citation>Masana L., Correig E., Ibarretxe D., Anoro E., Arroyo J.A., Jeric&#xf3; C., Guerrero C., Miret M., N&#xe4;f S., Pardo A., et al. Low HDL and high triglycerides predict COVID-19 severity. Sci. Rep. 2021;11 doi: 10.1038/s41598-021-86747-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-86747-5</ArticleId><ArticleId IdType="pmc">PMC8010012</ArticleId><ArticleId IdType="pubmed">33785815</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Cheng A., Kumar R., Fang Y., Chen G., Zhu Y., Lin S. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity. J.&#xa0;Med. Virol. 2020;92:2152&#x2013;2158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273060</ArticleId><ArticleId IdType="pubmed">32406952</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner J., Garcia-Rodriguez V., Yu A., Dutra B., Larson S., Cash B., DuPont A., Farooq A. Elevated transaminases and hypoalbuminemia in Covid-19 are prognostic factors for disease severity. Sci. Rep. 2021;11:10308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8119433</ArticleId><ArticleId IdType="pubmed">33986318</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>